Bullfrog AI Holdings, Inc. Warrants

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) announced the launch of bfARENAS™, a scenario-based decision engine designed to help biotech and pharmaceutical companies optimize drug portfolio strategy and clinical trial design. The new tool completes the company's end-to-end AI intelligence workflow by enabling head-to-head comparison of drug progr...

ProFound Therapeutics appointed Tom Chittenden as Chief Technology Officer and Laurel Ostrom as Chief Human Resources Officer to enhance their AI-driven drug discovery platform and organizational capabilities.

BullFrog AI, a technology-enabled drug development company, announced a strategic collaboration with Sygnature Discovery, a UK-based contract research organization. Through this collaboration, Sygnature will introduce BullFrog's AI-driven data insights platform, BullFrog Data Networks™, to its global biopharma client base.

GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on...

GAITHERSBURG, Md., March 08, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced the availability o...